Market News

Global Oligonucleotide Synthesis Market: Key Developments

In August 2021, Danaher Corporation, global life sciences and diagnostics, announced the acquisition of Aldevron, a provider of nucleic acids and proteins. This acquisition helped Danaher Corporation to expand its oligonucleotide product portfolio.
In June 2021, Twist Bioscience, is a public biotechnology company, announced the acquisition of iGenomX, a company offering multiplex library preparation tools for next-generation sequencing (NGS) workflows. The acquisition helped enhance Twist’s capabilities to support next-generation sequencing (NGS) preparations across the oligonucleotide synthesis market.
Global Oligonucleotide Synthesis Market- Cross Sectional Analysis:
Market players are focused on adopting inorganic strategies, such as collaborations, in order to expand its product portfolio and geographical presence in the market. In January 2022, Merck KGaA announced a collaboration with Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, to discover and develop oligonucleotide therapies for non-alcoholic steatohepatitis (NASH).
Global Oligonucleotide Synthesis Market: Key Trends
Introduction of oligonucleotide synthesis with advanced technology: Market players are engaged in inorganic activities such as collaboration for the innovation of new oligonucleotide equipment. This is expected to increase the growth of the global oligonucleotide synthesis market, over the forecast period For instance, On December 18, PeptiSystems, a company that offers a new generation of instruments for solid-phase synthesis production of peptide and oligonucleotide therapeutics, and CordenPharma, a full-service contract development and manufacturing organization (CDMO), entered into a collaboration agreement for testing and evaluation of a new generation of peptide synthesis technology. Under the terms of this agreement, CordenPharma will evaluate a new synthesis instrument, PeptiPilot, developed by PeptiSystems. It is based on flow through column technology. This technology can be used for process development and large-scale commercial manufacturing of peptides of non-GMP and GMP quality.